Cirena unveils high-purity long RNA products for CRISPR and genome-editing research
Cirena, a life sciences company headquartered at the BioFrontiers Institute, University of Colorado Boulder, has announced its public launch with a portfolio of long RNA products designed to support CRISPR, prime editing, and functional genomics workflows.
Addressing a longstanding synthesis challenge
Producing long RNA oligonucleotides without compromising sequence integrity has historically presented significant technical difficulties. Researchers requiring guide RNAs (gRNAs) and prime editing guide RNAs (pegRNAs) in the 100–400 nucleotide range have typically faced trade-offs between purity, turnaround time, and construct integrity. Cirena’s proprietary synthesis technology, developed by Prof. Marvin Caruthers – co-founder of Amgen and Applied Biosystems – and Dr Douglas Dellinger at the University of Colorado Boulder, aims to resolve these constraints.
Rapid turnaround and proven delivery
The company reports successful delivery of long RNA to academic and pharmaceutical research teams across the United States, Europe, and Japan prior to its public launch. Turnaround times are described as substantially shorter than conventional approaches, which have relied on ligation of shorter oligomers or extended purification processes.
“While many great companies reliably deliver short RNA, producing long RNA without compromising integrity is notoriously difficult,” said John Rinn, CEO of LincSwitch. “Cirena proved that they can reliably deliver 150nt RNA with exceptional quality across the U.S., enabling our team to confidently advance experiments without delays.”
Applications across research domains
Cirena’s RNA products are targeted at CRISPR base and prime editing, oncology research, vaccine development, and gene regulation studies. “Cirena enables this exploration by delivering high quality long RNA rapidly, thus eliminating the delays that have historically slowed innovation,” said Marv Caruthers, Co-Founder of Cirena.
For more information, visit: www.cirena.com
Digital issue: Please click here for more information
